Patents Issued in December 24, 2024
  • Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
    Patent number: 12171746
    Abstract: A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.
    Type: Grant
    Filed: January 11, 2020
    Date of Patent: December 24, 2024
    Assignees: Lipomedix Pharmaceuticals Ltd., Sharre Zedek Scientific Ltd.
    Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
  • Material and method for treating cancer
    Patent number: 12171747
    Abstract: Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: December 24, 2024
    Assignee: UROGEN PHARMA LTD.
    Inventors: Yulia Hionidi, Omer Tsipori, Marina Konorty
  • Nitroimidazole formulations
    Patent number: 12171748
    Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: December 24, 2024
    Assignee: IRP HEALTH PTY LTD
    Inventors: Zhicheng Xiao, David Xiang Yu, Colin William Pouton, Zhiyong He
  • Thioureylene liquid compositions
    Patent number: 12171749
    Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: December 24, 2024
    Assignee: NORBROOK LABORATORIES LIMITED
    Inventors: Louise Reynolds, Manish Umrethia
  • Isoxazoline parasiticide formulations and methods for treating blepharitis
    Patent number: 12171750
    Abstract: Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: December 24, 2024
    Assignee: Tarsus Pharmaceuticals, Inc.
    Inventors: Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
  • Methods of treating intraocular pressure with activators of Tie-2
    Patent number: 12171751
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: December 24, 2024
    Assignee: EyePoint Pharmaceuticals, Inc.
    Inventor: Kevin Peters
  • Methods of treating post-COVID condition(s)
    Patent number: 12171752
    Abstract: Disclosed is a method of treating post-COVID condition(s) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: December 24, 2024
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Crystalline forms of ALDH2 modulators
    Patent number: 12171753
    Abstract: Provided herein are novel crystalline forms of a compound that acts as an ALDH2 effector, processes for preparing the crystalline forms of the compound with or without coformer, and uses thereof.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: December 24, 2024
    Assignee: Sophrosyne Pharmaceuticals Limited
    Inventors: Lewis Feldberg, Akram Sabouni, Thomas R. Bailey, Vincent Wing-Fai Tai, Tom Leyssens
  • Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers
    Patent number: 12171754
    Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production are also described.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: December 24, 2024
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Peng Huang, Qiang Li
  • PAPD5 inhibitors and methods of use thereof
    Patent number: 12171755
    Abstract: The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 24, 2024
    Assignees: Children's Medical Center Corporation, Brigham & Women's Hospital, Inc.
    Inventors: Suneet Agarwal, Neha Nagpal, Yick Fong
  • NLRP3 modulators
    Patent number: 12171756
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: December 24, 2024
    Assignee: INNATE TUMOR IMMUNITY, INC.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • Crenolanib for treating FLT3 mutated proliferative disorders
    Patent number: 12171757
    Abstract: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: December 24, 2024
    Assignee: Arog Pharmaceuticals, Inc.
    Inventor: Vinay K. Jain
  • Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
    Patent number: 12171758
    Abstract: Disclosed herein is a solid Form A of 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine hydrochloride exhibiting at least X-ray lines (in degrees 2?±0.2) at 4.30, 8.59, 12.88, 18.82 and 21.34 in a powder diffraction pattern when measured using Cu K? radiation. The solid Form A is an antagonist of the kappa-opioid receptor (KOR) and is useful for treating conditions that benefit from the same. Compositions comprising the solid Form A, as well as related methods of use are also disclosed.
    Type: Grant
    Filed: July 3, 2024
    Date of Patent: December 24, 2024
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Brian Van Dyke, Yawei Shi, Mengya Ma, Lori Jean Van Orden
  • Methods and uses for treating anhedonia
    Patent number: 12171759
    Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
    Type: Grant
    Filed: March 14, 2024
    Date of Patent: December 24, 2024
    Assignee: Xenon Pharmaceuticals Inc.
    Inventor: Simon Neil Pimstone
  • Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
    Patent number: 12171760
    Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventor: Hazel Hunt
  • Vilazodone inclusion complexes, compositions and preparation thereof
    Patent number: 12171761
    Abstract: Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: December 24, 2024
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Dailong Fang, Xiaomiao Qiu, Beiyang Yao, Shuiwang Feng, Xin Huang, Jinsong You, Fangfang Huang
  • Sleep disorder treatment and prevention
    Patent number: 12171762
    Abstract: The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: December 24, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen C. Harris, Ram P. Kapil, Donald J. Kyle, Garth Whiteside
  • Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer
    Patent number: 12171763
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar
  • Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
    Patent number: 12171764
    Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 24, 2024
    Assignee: BIORA THERAPEUTICS, INC.
    Inventors: Mitchell Lawrence Jones, Sharat Singh, Christopher Loren Wahl, Harry Stylli, Kevin David Howe, Arana Perera
  • Combination therapies using PRMT5 inhibitors for the treatment of cancer
    Patent number: 12171765
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: December 24, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
    Patent number: 12171766
    Abstract: The present invention relates to methods of treating a human patient suffering from brain injury. These method may comprise (starting) administering to a selected patient within a time period of ?12 hours or within a time period of >12 hours after the occurrence of the brain injury a therapeutically effective amount of a biopterin compound such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin. The invention also relates to methods of increasing the value of the extended Glasgow Outcome Scale (eGOS) of patients suffering from brain injury, thereby improving the condition of the patient.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: December 24, 2024
    Assignee: VERINOS OPERATIONS GMBH
    Inventors: John Stover, Frank Tegtmeier
  • Uses of DPP IV inhibitors
    Patent number: 12171767
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: December 24, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • IRAK4 degraders and uses thereof
    Patent number: 12171768
    Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: December 24, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Jared Gollob, Jeffrey Davis, Alice Mcdonald, Haojing Rong
  • Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure
    Patent number: 12171769
    Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: December 24, 2024
    Assignees: BioMimetix JV, LLC, Duke University
    Inventors: Kathleen Ashcraft, Mark Dewhirst, Ines Batinic-Haberle, James D. Crapo
  • Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters
    Patent number: 12171770
    Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one. Pharmaceutical compositions and the dosage forms of the bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters can be used to treat any condition associated with testosterone deficiency, including complete absence of endogenous testosterone in male or female subjects.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: December 24, 2024
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
  • Tryptamine compositions for enhancing neurite outgrowth
    Patent number: 12171771
    Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: December 24, 2024
    Assignee: TURTLE BEAR HOLDINGS, LLC
    Inventor: Paul Edward Stamets
  • Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
    Patent number: 12171772
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: December 24, 2024
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: Gavin Hirst, Raja Reddy, Scott J. Hecker, Maxim Totrov, David C. Griffith, Olga Lomovskaya, Michael N. Dudley, Serge Henri Boyer
  • Inhibiting inflammation with milk oligosaccharides
    Patent number: 12171773
    Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: December 24, 2024
    Assignees: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias. Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Topical analgesic
    Patent number: 12171774
    Abstract: Provided herein is a topical analgesic composition that includes an external analgesic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical analgesic composition.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: December 24, 2024
    Inventors: Tony LaRosa, Robert Davidson, David Reid
  • Use of cladribine for treating autoimmune neuromuscular disease
    Patent number: 12171775
    Abstract: The present invention relates to the use of 2-chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 24, 2024
    Assignee: Chord Therapeutics SA
    Inventor: Konrad Rejdak
  • Methods for treatment and prophylaxis of HIV and AIDS
    Patent number: 12171776
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: December 24, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • Methods of making a cyclic dinucleotide
    Patent number: 12171777
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: May 1, 2023
    Date of Patent: December 24, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • Methods of treating myelodysplastic syndrome
    Patent number: 12171778
    Abstract: This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: December 24, 2024
    Assignee: Geron Corporation
    Inventors: Aleksandra Rizo, Jacqueline Cirillo Bussolari
  • Regulated drug delivery via controlled degradable chondroitin sulfate particles
    Patent number: 12171779
    Abstract: Disclosed herein are crosslinked chondroitin sulfate particles crosslinked chondroitin sulfate particle polyelectrolytes. The particles are useful in drug delivery applications. The particles may be used to treat various conditions, including bacterial and fungal infections.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: December 24, 2024
    Assignee: University of South Florida
    Inventors: Nurettin Sahiner, Ramesh Ayyala
  • Polysilane methacrylic compounds and methods of making them
    Patent number: 12171780
    Abstract: A polysilane methacrylic polymer and processes of preparing the polysilane methacrylic polymer are provided.
    Type: Grant
    Filed: July 17, 2024
    Date of Patent: December 24, 2024
    Assignee: Zetagen Therapeutics, Inc.
    Inventor: Bryan S. Margulies
  • Stable, highly pure L-cysteine compositions for injection and methods of use
    Patent number: 12171781
    Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: December 24, 2024
    Assignee: EXELA PHARMA SCIENCES, LLC
    Inventors: John Maloney, Aruna Koganti, Phanesh Koneru
  • Formulation, use and method for broad-spectrum prophylaxis and treatment of viral infections caused by SARS-CoV-2 and other emergent viruses
    Patent number: 12171782
    Abstract: EGCG-Zn2+ molecular complexes exhibit a significantly higher affinity than the EGCG molecule alone or Zn2+ alone for binding to different SARS-CoV-2 molecular targets and show virtually complete antiviral suppressive activity (>99%) against this virus in experimental models of infection. EGCG-Zn2+ complexes have a lower toxicity than EGCG alone in transfected human cells. The combination of EGCG and Zn2+, significantly improved some key pharmacokinetic parameters of EGCG in humans. Thus, these complexes can be used as a new broad-spectrum method for chemoprophylaxis or treatment of viral diseases by using formulations containing a composition of EGCG and Zn2+ or EGCG-Zn2+ complexes in sufficient amount to reach a blood concentration with antiviral effect, minimizing safety issues in humans.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: December 24, 2024
    Assignee: MELISA INSTITUTE, GENOMICS & PROTEOMICS RESEARCH SpA
    Inventor: Elard Koch
  • Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
    Patent number: 12171783
    Abstract: The subject matter disclosed herein is generally directed to compositions and methods for treating diffuse gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-gliomas). Disclosed herein are gene signatures specific for tumor cell types and compositions for treatment of H3K27M gliomas. In one embodiment, PRC1 is targeted in a treatment regimen for H3K27M-gliomas.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 24, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Mario Suva, Bradley Bernstein, Aviv Regev, Mariella Filbin, Itay Tirosh, Volker Hovestadt
  • Platelet lysate compositions and uses thereof
    Patent number: 12171784
    Abstract: The present invention relates to compositions, kits, and methods for providing mechanical support and/or agents to biological targets. Specifically, the compositions comprise platelet lysate, fibrinogen and thrombin. The compositions can be used for the treatment of wounds/injuries (e.g. corneal), and for other applications including tissue culture.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: December 24, 2024
    Assignee: iFix Medical Pty Ltd
    Inventors: Gerard Sutton, JingJing You, Hannah Frazer
  • Pluripotent cells derived from bone marrow and methods for isolation
    Patent number: 12171785
    Abstract: The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: December 24, 2024
    Assignees: Regents of the University of Minnesota, HEALIOS K.K.
    Inventors: Leo T. Furcht, Catherine M. Verfaillie, Morayma Reyes
  • Use of mesenchymal stem cells for the treatment of inflammation
    Patent number: 12171786
    Abstract: Provided are methods of determining whether a mammalian subject having an inflammatory condition (e.g., an oral inflammatory condition) will respond positively to mesenchymal stem cell (MSC) therapy, as well as method of treating such inflammatory conditions by administering MSCs.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 24, 2024
    Assignee: The Regents of the University of California
    Inventors: Boaz Arzi, Emily Mills Ko, Dori L Borjesson
  • Methods and compositions for modulating angiogenesis and vasculogenesis
    Patent number: 12171787
    Abstract: Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: December 24, 2024
    Assignee: SanBio, Inc.
    Inventors: Monique Dao, Ciara Tate, Casey C. Case
  • Methods and materials for treating lung disorders
    Patent number: 12171788
    Abstract: This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: December 24, 2024
    Inventor: Gary M. Petrucci
  • Immunological extract and method of production
    Patent number: 12171789
    Abstract: The present invention relates to a method of preparing an extract from edible bird's nest, a bird's nest extract and uses of the bird's nest extract. The method comprises preparing an edible bird's nest (EBN) mixture; and contacting the mixture with an extraction solution to bind a molecule in the mixture, wherein the extraction solution comprises at least one binding moiety selected from the group comprising an opsonin binding moiety, a complement protein binding moiety, a lectin binding moiety, a ficolin binding moiety, a collectin binding moiety, and a pentraxin binding moiety.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: December 24, 2024
    Inventor: Kah Meng Lim
  • Microorganisms engineered to reduce hyperphenylalaninemia
    Patent number: 12171790
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: December 24, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
  • Cancer therapy with live attenuated bacteria
    Patent number: 12171791
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: December 24, 2024
    Assignee: Prokarium Limited
    Inventors: Livija Deban, Nicholas Glanville
  • Bacillus strains for improving feed conversion rates and body weight gain in animals
    Patent number: 12171792
    Abstract: Compositions comprising Bacillus pumilis O72NR7 (deposit accession number DSM 32563) are useful for improving myriad performance parameters when fed to animals, including, but not limited to, body weight gain, average daily gain and feed conversion rates. The present disclosure describes animal feed additives and animal feeds comprising Bacillus pumilis O72NR7.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: December 24, 2024
    Assignee: Novozymes A/S
    Inventors: Adam Nelson, Erik Eckhardt, Estelle Devillard, Meagan Hale, Emily Zhang, Ethan Chad Baker
  • Method of activating lactic acid bacteria
    Patent number: 12171793
    Abstract: The present invention relates to methods of activating live lactic acid bacteria comprising exposing said bacteria to a preparation comprising citrate, wherein said bacteria have the ability to utilize citrate as an external electron acceptor. The present invention further relates to methods to enhance the activity of certain live bacteria in mammals. More specifically the invention relates to improve the wake-up of certain lactic acid bacteria from the freeze-dried state. The present invention also relates to preparations comprising said activated bacteria and therapeutic uses of said activated bacteria.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: December 24, 2024
    Assignee: INFANT BACTERIAL THERAPEUTICS AB
    Inventors: Staffan Stromberg, Eamonn Connolly, Stefan Roos
  • Gene therapy for ciliopathies
    Patent number: 12171794
    Abstract: There is described a vector for treating a ciliopathy such as Bardet-Biedl syndrome, wherein the vector comprises a promoter operably linked to a ciliopathy gene, wherein the vector can provide transduction of the ciliopathy gene into multiple organs, wherein the promoter is a ubiquitous promoter which can provide expression of the ciliopathy gene in the transduced organs, and wherein the ciliopathy gene encodes a functional protein corresponding to the protein that is mutated in the ciliopathy. Also described is the use of the above vector in a method of treating a ciliopathy, the method comprising administering a therapeutically effective amount of the vector to a patient suffering from a ciliopathy.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 24, 2024
    Assignee: UCL BUSINESS LTD
    Inventors: Philip Beales, Victor Hernandez
  • Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
    Patent number: 12171795
    Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: December 24, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Philipp Mueller, Klaus Erb, Patrik Erlmann, Guido Wollmann